Pembrolizumab,Lenvatinib,Sunitinib,ipilimumab
Merck,Pfizer,eisai,bms
['melanoma', ' ipi ']
 favorable risk patients just don t seem inflamed enough to derive ici benefit. in melanoma, post pd1 reccurance much more common than post ctla4. maybe a little ipi throughout can make those recurrences at 2+ years more durable. lots of hypotheses to be generated.
Vanderbilt MD/PhD Student- focused on providing Personalized Oncology Care. Bass Player in the CheckPoints. Studying the TME in RCC. Views are my own!